Mesenchymal stem cell-derived exosomes as new remedy for the treatment of inflammatory eye diseases

Detrimental immune response has a crucially important role in the development and progression of inflammatory eye diseases. Inflammatory mediators proteolytic enzymes released by activated cells induce serious injury corneal epithelial retinal ganglion cell which may result vision loss. Mesenchymal stem (MSCs) are regulatory produce various immunosuppressive factors that modulate phenotype function cells. However, several safety issues, including undesired differentiation emboli formation, limit clinical use MSCs. MSC-derived exosomes (MSC-Exos) nano-sized extracellular vesicles contain all immunoregulatory factors. Intraocular administration MSC-Exos efficiently attenuated inflammation significantly improved visual acuity experimental animals without causing any severe side effects. As cell-free product, addressed issues related to transplantation Therefore, could be considered as potentially new remedy for treatment diseases efficacy should explored up-coming trials.